CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, Sebastian Francis et al.|Blood Advances|2023Cited by 32
Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential ThrombocythemiaRodrigo Gil-Manso, Alberto Álvarez‐Larrán, Gonzalo Carreño et al.|Blood|2023Cited by 1
Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre ExperienceAlberto Blanco Sánchez, Gonzalo Carreño‐Tarragona, Rodrigo Gil-Manso et al.|Cancers|2024Cited by 1
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemiaGonzalo Carreño‐Tarragona, On behalf of the MPN Spanish Group (GEMFIN), Rodrigo Gil-Manso et al.|Leukemia|2026Cited by 0